NGENLA (somatrogon) for the Treatment of Paediatric Growth Hormone...
NGENLA (somatrogon) is a human growth hormone analogue for the treatment of growth failure in children aged three years and older.The post NGENLA (somatrogon) for the Treatment of Paediatric Growth...
View ArticleStelara for the Treatment of Moderate to Severe Crohn’s Disease, US
Developed by Janssen Biotech, Stelara is a biologic therapy indicated for the treatment of multiple indications, including moderate to severely active Crohn's disease, active ulcerative colitis (UC),...
View ArticleInnoCare receives clearance for leukaemia/lymphoma trial in China
InnoCare received IND clearance for a trial of ICP-248 plus orelabrutinib in China for lymphocytic leukaemia /small lymphocytic lymphoma.The post InnoCare receives clearance for leukaemia/lymphoma...
View ArticleVeopoz for the Treatment of Chaple Disease, US
Veopoz (pozelimab) is a complement inhibitor indicated for the treatment of adult and paediatric patients aged one and older with Chaple disease, also called CD55-deficient protein-losing enteropathy...
View ArticleSativex (Nabiximols) for the Treatment of Multiple Sclerosis, Europe
Sativex®, also known as Nabiximols, is indicated to treat spasticity due to multiple sclerosis and cancer pain.The post Sativex (Nabiximols) for the Treatment of Multiple Sclerosis, Europe appeared...
View ArticlePhesgo for the Treatment of HER2-Positive Breast Cancer, US
Phesgo is a fixed-dose combination (FDC) of Perjeta and Herceptin with hyaluronidase for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and HER2-positive...
View ArticleVabysmo (faricimab-svoa) for the Treatment of Neovascular Age-Related Macular...
Vabysmo™ (faricimab-svoa) is indicated for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema.The post Vabysmo (faricimab-svoa) for the Treatment of...
View ArticleHYQVIA for the Treatment of Chronic Inflammatory Demyelinating...
HYQVIA can treat primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP).The post HYQVIA for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy, USA...
View ArticleRezdiffra for the Treatment of Noncirrhotic Non-alcoholic Steatohepatitis, US
Rezdiffra (resmetirom) is a novel therapeutic indicated alongside diet and exercise for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver...
View ArticleRepatha for the Treatment of Heterozygous and Homozygous Familial...
Repatha (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) for lowering cholesterol in patients.The post Repatha for the Treatment of...
View ArticleRituxan for the Treatment of Non-Hodgkin’s Lymphoma, US
Rituxan (rituximab) is a prescription medicine indicated to treat blood cancers, autoimmune diseases and inflammatory conditions, including follicular lymphoma (FL), non-Hodgkin’s lymphoma (NHL),...
View ArticleRuzurgi (amifampridine) for the Treatment of LEMS
Ruzurgi (amifampridine) is the first medicine approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in paediatric patients.The post Ruzurgi (amifampridine) for the Treatment of LEMS...
View ArticlePENBRAYA (Meningococcal A, B, C, W, and Y vaccine) for the Prevention of...
PENBRAYA is the first pentavalent vaccine to protect adolescents against the most common types of meningococcal disease.The post PENBRAYA (Meningococcal A, B, C, W, and Y vaccine) for the Prevention of...
View ArticleNEXLETOL (bempedoic acid) for the Treatment of Heterozygous Familial...
NEXLETOL and NEXLIZET are oral non-statin cholesterol-lowering drugs developed by US pharmaceutical company Esperion Therapeutics.The post NEXLETOL (bempedoic acid) for the Treatment of Heterozygous...
View ArticleUltomiris (ravulizumab-cwvz) for Paroxysmal Nocturnal Haemoglobinuria
Ultomiris™ (ravulizumab) is a complement inhibitor drug approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults.The post Ultomiris (ravulizumab-cwvz) for Paroxysmal Nocturnal...
View ArticleXOLREMDI (mavorixafor) for the Treatment of WHIM Syndrome, USA
XOLREMDI (mavorixafor), a CXCR4 antagonist, is the first approved therapy indicated to treat patients with WHIM syndrome.The post XOLREMDI (mavorixafor) for the Treatment of WHIM Syndrome, USA appeared...
View ArticleBreyanzi for the Treatment of Large B-cell Lymphoma, US
Breyanzi (lisocabtagene maraleucel) is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory (r/r) large B-cell...
View ArticleWinrevair (Sotatercept) for the Treatment of Pulmonary Arterial Hypertension,...
Winrevair (sotatercept) is a novel biologic therapy to treat rare and progressive pulmonary arterial hypertension (PAH).The post Winrevair (Sotatercept) for the Treatment of Pulmonary Arterial...
View ArticleLynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer
The Phase III PROpel trial supported the FDA's approval of Lynparza in combination with abiraterone and prednisone or prednisolone.The post Lynparza (olaparib) for the Treatment of BRCA-mutated...
View ArticleSoliris (Eculizumab) for the Treatment of Generalised Myasthenia Gravis...
Soliris (eculizumab) is a monoclonal antibody indicated for the treatment of rare and severe blood disorders, including PNH and aHUS.The post Soliris (Eculizumab) for the Treatment of Generalised...
View Article